Evercore ISI analyst Vijay Kumar is adding Danaher to the firm’s “Tactical Outperform” list ahead of earnings from the MedTech, Life Science Tools and Diagnostics group, stating that the firm has “a distinct bias towards mega caps and value/GARP as we head into” Q2. Evercore has an Outperform rating and $260 price target on Danaher shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DHR: